GlassScriptPhysician profile
Chase Contino
NPI 1538429048
$33,435.11
in general payments reported to CMS, 2019-2025
31 companies · $3,710 in 2025
The $3,710 reported for 2025 was more than what a typical Clinical Cardiac Electrophysiology provider received nationally (typical 2025 total: $2,477).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15K · 2020: $9,278 · 2021: $779 · 2022: $1,158 · 2023: $945 · 2024: $2,830 · 2025: $3,710.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $3,961 · Food and Beverage: $3,524.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $3,961.17 |
| Food and Beverage | $3,524.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $12,853.10 | 2019-2020 | |
| Boston Scientific Corporation | $9,772.20 | 2019-2025 | Watchman Flx, General - Crm_crm, Lux-Dx Insertable Cardiac Monitor |
| Abbott Laboratories | $3,565.80 | 2019-2025 | Aveir, Gallant, Jot Dx |
| Medtronic, INC. | $2,022.87 | 2021-2025 | Evera Mri Xt Dr Surescan, Micra, Aurora Ev-Icd Mri Surescan |
| Philips North America LLC | $1,537.23 | 2022-2025 | Igt Devices Undivided, (9520) Igt Devices Undivided, Lm Accessories |
| Medical Device Business Services, INC. | $1,109.92 | 2019 | |
| Novartis Pharmaceuticals Corporation | $481.54 | 2021-2025 | |
| Biosense Webster, INC. | $246.34 | 2019-2022 | |
| Cvrx, INC. | $242.19 | 2023-2025 | Barostim Neo System |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $185.83 | 2022-2025 | Lifevest |
| Amgen INC. | $162.65 | 2020-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $156.03 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $127.92 | 2019-2025 | Camzyos, Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $120.87 | 2019-2024 | Jardiance |
| Merck Sharp & Dohme LLC | $114.88 | 2022-2025 | Verquvo, Capvaxive |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotronik INC. | $102.15 | 2019 | |
| Abiomed | $80.51 | 2024-2025 | Impella |
| Astrazeneca Pharmaceuticals LP | $78.11 | 2021-2023 | Farxiga, Lynparza |
| Scpharmaceuticals INC. | $70.06 | 2024 | |
| Pfizer INC. | $63.19 | 2020-2023 | |
| Sanofi-Aventis U.S. LLC | $61.84 | 2023-2024 | |
| Novo Nordisk INC | $61.29 | 2021-2025 | Wegovy |
| Amarin Pharma, INC. | $58.31 | 2020-2021 | |
| Cardiva Medical, INC. | $31.79 | 2019-2021 | |
| Chiesi USA, INC. | $24.74 | 2025 | Juxtapid |
| Kestra Medical Technology Services, INC. | $23.78 | 2025 | Assure Wcd |
| Atricure, INC. | $18.84 | 2025 | Atriclip Laa Exclusion System, Synergy Ablation System |
| United Therapeutics Corporation | $18.33 | 2025 | Tyvaso |
| Actelion Pharmaceuticals US, INC. | $16.99 | 2025 | Uptravi |
| Angiodynamics, INC. | $13.03 | 2021 | |
| Daiichi Sankyo INC. | $12.78 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chase Contino listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.